Down-Regulation of Bcl-2 Is a Potential Marker of the Efficacy of Progestin Therapy in the Treatment of Endometrial Hyperplasia
- 30 April 1999
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 73 (1), 126-136
- https://doi.org/10.1006/gyno.1998.5336
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Expression of Bcl-2 and Bax in cultured normal human keratinocytes and melanocytes: relationship to differentiation and melanogenesisBritish Journal of Dermatology, 1997
- bcl-2 Expression in Endometrial Hyperplasia and CarcinomaGynecologic Oncology, 1996
- Antagonism between estradiol and progestin on Bcl-2 expression in breast-cancer cellsInternational Journal of Cancer, 1996
- Immunohistochemical Analysis of Endometrial Adenocarcinoma for bcl-2 and p53 in Relation to Expression of Sex Steroid Receptor and Proliferative ActivityInternational Journal of Gynecological Pathology, 1996
- Persistent expression of bcl-2 onco-protein in endometrial carcinoma correlates with hormone receptor positivityInternational Journal of Gynecologic Cancer, 1996
- Cyclic bcl-2 gene expression in human uterine endometrium during menstrual cycleThe Lancet, 1994
- Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptorCancer Letters, 1992
- Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell deathNature, 1990
- Estradiol and progesterone receptors in normal and neoplastic endometrium: Correlations between receptors, histopathological examinations and clinical responses under progestin therapyInternational Journal of Cancer, 1979
- Progestin therapy in endometrial hyperplasiaGynecologic Oncology, 1974